Knowthestock.com
CUR - Neuralstem, Inc.

Sell

Weak GrowthEarnings/Profit is Negative

25%

based on last 5 year data.
Income Statement is WEAK
Revenue Growth is -12.17%
Operating Income is Negative
Net Income is Negative
Earnings Per Share (EPS) is Negative but improving
Net Margin is -102704.03%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 14.96
Debt Ratio is 0.07
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.0
Cash Flow is WEAK
Cash from Operations is Negative
Capital Expenditure not available
Net Increase in Cash is Positive
Long Term Score Trend is NEUTRAL
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Neuralstem, Inc. (CUR) - http://www.neuralstem.com
Neuralstem, Inc. operates as a biopharmaceutical company, which engages in the research, development, and commercialization of central nervous system therapies based on human neuronal stem cells and small molecule compounds. Its pipeline includes NSI-189 small molecule program, NSI-566 stem cell therapy program, and novel & proprietary chemical entity screening platform. The company was founded by I. Richard Garr, Karl Y. Johe, and Merrill Solomon in 1996 and is headquartered in Germantown, MD.
Exchange - NASDAQ
Industry - Biotechnology
Sector - Health Technology
CEO - Kenneth C. Carter
Employees - 6
    Close


Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.